High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection.
Level III
Where this comes from
- Record sourced from PubMed, PMID 32703883.
- Also identified by DOI 10.1136/thoraxjnl-2020-214993.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This observational study aims to assess the outcome and safety of O<sub>2</sub>-therapy by high-flow nasal cannula (HFNC) in 28 consecutive patients with severe hypoxemic acute respiratory failure (hARF) consequent to SARS-CoV-2 infection, unresponsive to conventional O<sub>2</sub>-therapy. Nineteen patients had a positive response. Nine patients required escalation of treatment to non-invasive ventilation (five subsequently intubated). None of the staff had a positive swab testing during the study period and the following 14 days. Severity of hypoxemia and C reactive protein level were correlated with HFNC failure. These data suggest HFNC to be a safe treatment for less severe patients with SARS-CoV-2 hARF and efficacy will need to be assessed as part of a clinical trial.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Hypoxia
- Oxygen Inhalation Therapy
- Pneumonia, Viral
- Respiratory Insufficiency